Methadone

The Worldwide Opioids Industry is Expected to Reach $6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022
Alternative Medicine, Pharmaceutical, Health, Analgesic, Morphine, Back pain, Codeine, Pain management, Pain, Methadone, Neuropathic pain, Cannabis, Cancer pain, Lists of countries and territories, Diarrhea, Patient, Oxycodone, Fentanyl, Cancer, Incidence, Cough, Hydrocodone, Chronic pain, CAGR, Growth, Migraine, Poultry

The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.

Key Points: 
  • The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.
  • Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea.
  • The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain.
  • Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market.

RECOVERY CENTERS OF AMERICA AND MAPDA (MOTHERS AGAINST PRESCRIPTION DRUG ABUSE) 2022 SCHOLARSHIP WINNERS COMMITTED TO THE FIGHT AGAINST ADDICTION

Retrieved on: 
Tuesday, April 19, 2022
Patient, Family, CEO, The Honourable, Gaps, Appalachian State University, Addiction, Fashion Institute of Technology, Technical, Opioid overdose, High Watch Recovery Center, Life, State university system, Topical steroid withdrawal, Goal, SUD, Public relations, Newsweek, RCA, Student, Love, Insurance, Sexual abuse, Janes, Methadone, MA, Emergent Design, Nicotine, Mother, Darkness, Partnership, Disease, School of Industrial Art and Technical Design for Women, Hope, Pharmaceutical industry, Residential care, Management, Telescopic sight, Medicine, Technology, Pharmacology

KING OF PRUSSIA, Pa., April 19, 2022 /PRNewswire/ -- Recovery Centers of America (RCA) continues to support furthering education to treat those battling substance use disorder (SUD) by today announcing three outstanding winners of this year's Hope for Addiction Scholarships.

Key Points: 
  • Zach battled addiction for many years before hitting rock bottom and entering a recovery program in 2014.
  • The second Hope for Addiction Scholarship the RCA/ MAPDA Scholarship is awarded to Sara Solomon from Bridgewater, Massachusetts.
  • Recovery Centers of America (RCA) is a national network of substance use disorder treatment facilities inthe United States.
  • RCA's mission is to help 1 million patients achieve a life of recovery through evidence-based alcohol and drug addiction treatment.

Aegis Treatment Centers Opens Third Location in Bakersfield to Help Individuals Struggling with Opioid Addiction

Retrieved on: 
Tuesday, March 22, 2022
Hospital, American Medical Association, Passages Malibu, Heroin, Buprenorphine, Patient, Adult, Pinnacle, Research, Methamphetamine, Opioid, CEO, Aegis, Suite, Medi-Cal, Battleship, Cocaine, United States drug overdose death rates and totals over time, United States Navy, Indian Medical Association, Taiwan Centers for Disease Control, Center, Fentanyl, FDA, Education, Opioid use disorder, MAT, Drug overdose, Methadone, Pharmaceutical industry, Medical device, Health insurance, Medicare

BAKERSFIELD, Calif., March 22, 2022 /PRNewswire/ -- Aegis Treatment Centers , the largest outpatient treatment provider in California for opioid addiction, has opened its third opioid treatment program in Bakersfield.

Key Points: 
  • BAKERSFIELD, Calif., March 22, 2022 /PRNewswire/ -- Aegis Treatment Centers , the largest outpatient treatment provider in California for opioid addiction, has opened its third opioid treatment program in Bakersfield.
  • Aegis also operates treatment centers on 21st and Columbus streets, both in Bakersfield.
  • "The past two years have been extremely difficult on everyone, and especially those already struggling with addiction.
  • Headquartered in New Jersey, Pinnacle Treatment Centers is a recognized leader in comprehensive drug and alcohol addiction treatment serving nearly 35,000 patients daily in California (Aegis Treatment Centers), Georgia (HealthQwest), Indiana, Kentucky, New Jersey, Ohio, Pennsylvania, and Virginia.

Purdue Pharma L.P. to Provide Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal in Emergency Medicine Settings

Retrieved on: 
Thursday, March 17, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vitae, Curriculum, Company, Risk, Recurrence, National, Purdue Pharma, Letter, Curriculum vitae, Emergency department, EMS, Public health, Mortality, Buprenorphine, Caregiver, Role, Pulmonary edema, Ventricular fibrillation, Doctor of Pharmacy, Medical Affairs Bureau, Research, Hypoventilation, CT, Patient, Hypertension, Bankruptcy, Oxygen, Nalmefene, Methadone, LAAM, Ventricular tachycardia, Opioid overdose, Naloxone, The New England Journal of Medicine, Knowledge, IIR, Tachycardia, Hypotension, FDA, Hypersensitivity, Opioid, Emergency medical services, Pharmaceutical industry, Generic drug, Science

Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to assess opioid overdose reversal in Emergency Department (ED) and Emergency Medical Service (EMS) settings.

Key Points: 
  • Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to assess opioid overdose reversal in Emergency Department (ED) and Emergency Medical Service (EMS) settings.
  • This initiative aims to support researchers pursuing studies to help advance our knowledge and understanding of opioid overdose reversal in emergency medicine.
  • Additional information can be found on the Investigator-Initiated Research page of the Purdue Pharma website.
  • Pulmonary edema, cardiovascular instability, hypotension, hypertension, ventricular tachycardia, and ventricular fibrillation have been reported in connection with opioid reversal in both postoperative and emergency department settings.

Painesville Treatment Services opens to provide opioid addiction treatment for community

Retrieved on: 
Wednesday, March 9, 2022
National Center for Health Statistics, MAT, Medical statistics, Employment, Survival, Pinnacle, FDA, Anger, Hope, Topical steroid withdrawal, Nursing, Counselor, Recovery, Fentanyl, Ohio Department of Health, Medicaid, Health, University Hospitals Cleveland Medical Center, Ohio Department of Job and Family Services, Coronavirus, United States Navy, Grief, Patient, Heroin, Buprenorphine, Drug overdose, Medicare, National Center for Spinal Disorders, Pregnancy, Methadone, Opioid, Center, Drug, Hospital, Pharmaceutical industry

PAINESVILLE, Ohio, March 9, 2022 /PRNewswire/ -- Pinnacle Treatment Centers , a leader in providing accessible, affordable treatment for individuals struggling with drug and alcohol addiction, has opened Painesville Treatment Services in Lake County, Ohio.

Key Points: 
  • PAINESVILLE, Ohio, March 9, 2022 /PRNewswire/ -- Pinnacle Treatment Centers , a leader in providing accessible, affordable treatment for individuals struggling with drug and alcohol addiction, has opened Painesville Treatment Services in Lake County, Ohio.
  • Located at 1544 Mentor Avenue in Painesville, the community-based program serves as Pinnacle's 19th outpatient opioid addiction treatment center in the Buckeye State.
  • Painesville Treatment Services provides medication-assisted treatment (MAT), particularly methadone, at the facility.
  • In addition to innovative clinical and medical care, Painesville Treatment Services' compassionate team of doctors, nurses, counselors, and support staff offers hope and refuge.

Berkshire Biomedical, Developers of COPATM, Featured as a 2022 Top Texas Tech Startup in StartupCity Magazine

Retrieved on: 
Monday, March 7, 2022
Risk, COPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Methadone, Patient, Medical assistant, Food, Opioid, Opioid use disorder, Medicine, Knowledge, Berkshire, Company, Chronic pain, Dentition, De novo, Technology, Pharmaceutical industry, Medical device

DALLAS, March 7, 2022 /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or "the Company") is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness. The Company announced today that its lead product, the Computerized Oral Prescription Administration System (COPA™), has been honored as a 2022 Top Texas Tech Startup in the new edition of StartupCity Magazine. The COPA is a novel, oral liquid dispensing system specifically designed to deliver accurate and precise doses of prescription medications only to a biometrically authenticated Intended User, with the goal of enhancing patient wellness by providing remote monitoring with advanced data analytics that are not dependent on patient self-reporting, allowing for improved adherence and informed medical decisions. A link to the full article can be found here.

Key Points: 
  • DALLAS, March 7, 2022 /PRNewswire/ --Berkshire Biomedical Corporation ("Berkshire" or "the Company") is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness.
  • The Company announced today that its lead product, the Computerized Oral Prescription Administration System (COPA), has been honored as a 2022 Top Texas Tech Startup in the new edition of StartupCity Magazine.
  • This creates significant challenges to healthcare providers who are making medical decisions for patients without the accurate knowledge of the patient's medication adherence."
  • Berkshire is developing drug dispensing technologies designed to accurately and precisely deliver oral liquid drugs.

FDA Approves Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) for the Treatment of Known or Suspected Opioid Overdose with Natural or Synthetic Opioids

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Risk, Role, The New England Journal of Medicine, Opioid, Purdue Pharma, Hypoventilation, Tachycardia, Ventricular tachycardia, Prevalence, Public health, Hypotension, COVID-19, Buprenorphine, Nalmefene, Company, Bankruptcy, National, LAAM, Naloxone, Hypersensitivity, Recurrence, Oxygen, Caregiver, FDA, Hypertension, Patient, Pulmonary edema, Ventricular fibrillation, MD, CEO, Methadone, Mortality, CT, Pharmaceutical industry, Generic drug, Science

This FDA approval is an example of our ongoing efforts to help provide much-needed treatment for patients and health care providers.

Key Points: 
  • This FDA approval is an example of our ongoing efforts to help provide much-needed treatment for patients and health care providers.
  • Nalmefene Hydrochloride Injection is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection, like all drugs in this class, is not the primary treatment for ventilatory failure.

Santé Center for Healing's Expert Commentary on Stigma Surrounding Opioid Use Disorder

Retrieved on: 
Thursday, February 3, 2022
Awareness, USA TODAY, Patient, OUD, Injury, University, Methadone, Adolescent health, Medical director, Journal of Adolescent Health, Opioid, Naltrexone, Adolescence, Mega, Employment, Buprenorphine, Prevalence, Substance abuse, Public health, Prejudice, Social, Powerball, Sauter, Opioid use disorder, FDA, Super Bowl, Policy, Social Problems, Hospital Sant Joan de Déu Barcelona, Pharmaceutical industry, Cereal, Residential care

"The underlying cause of patients' opioid use disorder is very complicated, and stigma around their opioid use creates barriers for people to access care.

Key Points: 
  • "The underlying cause of patients' opioid use disorder is very complicated, and stigma around their opioid use creates barriers for people to access care.
  • But opioid use is more than personal choices, as external factors out of someone's direct control could also have an impact.
  • (4)
    The stigma on addiction extends to a stigma on treatment as well, as only 49% of Americans believe that there is an effective long-term treatment for opioid use disorder.
  • Opioid Use Disorder Stigma, Discrimination, and Policy Attitudes in a National Sample of U.S. Young Adults.

BayMark Acquires Granite Recovery Centers in New Hampshire

Retrieved on: 
Tuesday, December 21, 2021
CDC, MAT, Patient, Passages Malibu, Sud, Mental health, Topical steroid withdrawal, Methamphetamine, Opioid use disorder, Hospital, PHP, Adult, Acquisition, Plasma protein binding, COVID-19, OUD, Cocaine, SUD, Center, Methadone, Substance, Health care, IOP

Granite Recovery Centers has two residential treatment facilities and a number of sober living homes throughout southern New Hampshire that serve adult patients from across New England and throughout the country.

Key Points: 
  • Granite Recovery Centers has two residential treatment facilities and a number of sober living homes throughout southern New Hampshire that serve adult patients from across New England and throughout the country.
  • Since December of 2020, BayMark has grown its residential treatment services significantly adding facilities in Maine, West Virginia, Louisiana, Georgia and now New Hampshire.
  • In addition to Granite Recovery Centers, BayMark operates medication-assisted treatment facilities in Hudson, Newington, Salem and Somersworth, NH offering methadone and Suboxone, as well as counseling, for the treatment of Opioid Use Disorder.
  • Granite Recovery Centers was represented by Covington Associates Investment Banking and legal advisors Nixon Peabody throughout the acquisition.

Methadone Hydrochloride (CAS 1095-90-5) Global Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 20, 2021
Chemicals, Plastics, Manufacturing, Methadone, Industry, CAS, Generic drug

The "Methadone hydrochloride (CAS 1095-90-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Methadone hydrochloride (CAS 1095-90-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Methadone hydrochloride.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Methadone hydrochloride global market report key points: